dual aurora/Flt 4 inhibitors (Sareum)

N/A

Report date: 2025/03/19 20:00:56

NME

Base Information

Drug Namedual aurora/Flt 4 inhibitors (Sareum)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSerine/threonine-protein kinase Aurora-B inhibitorsVascular endothelial growth factor receptor 3 antagonistsSerine/threonine-protein kinase Aurora-A inhibitors

TargetsVascular endothelial growth factor receptor 3Serine/threonine-protein kinase Aurora-ASerine/threonine-protein kinase Aurora-B

Therapy Area/IndicationsUrinary Bladder NeoplasmsColonic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSareum Holdings plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSareum Holdings plc

Active IndicationsN/A

Inactive IndicationsUrinary Bladder NeoplasmsColonic Neoplasms

Other Information

ATC CodeN/A